2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and similar compounds as CYP11A1 inhibitors for the treatment of prostate cancer

A method for the treatment of a steroid receptor dependent condition or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof

• wherein
• A is a 3-10 membered carbocyclyl or a 4-12 membered heterocyclyl containing 1-4 heteroatoms selected from O, N, and S;
• B is
• C is
• G1 is CH2, NH, or O;
• G2 and G3 are, independently, CH or N;
• Z is —C(O)—, —SO2—, —C1-3 alkyl-, or —CH2—C(O)—;
• L is a bond, —C1-7 alkyl-, or —C1-7 alkenyl-;
• R1 is hydrogen, C1-7 alkyl, C1-7 alkoxy, halogen, hydroxy, nitro, halogen C1-7 alkyl, hydroxy C1-7 alkyl, —O-halogen C1-7 alkyl, or —X—NR6R7;
• R2 is hydrogen, hydroxy, C1-7 alkyl, or halogen;
• R3 is hydrogen, C1-7 alkyl, or amino;
• R4 is hydrogen, C1-7 alkyl, C1-7 alkoxy, halogen, hydroxy, hydroxy C1-7 alkyl, halogen C1-7 alkyl, or —C(O)—O—C1-7 alkyl;
• R5 is hydrogen, halogen, C1-7 alkoxy, or C1-7 alkyl;
• X is a bond or C1-7 alkyl;
• and
• R6 and R7 are, independently, hydrogen or C1-7 alkyl.

A compound of formula (I) or a pharmaceutically acceptable salt thereof

• wherein:
• B is
• such that
• i) when B is
• then
• A is:
• C is:
• G1 is CH2, NH or O;
• G2 and G3 are, independently, CH or N;
• Z is —C(O)—, —SO2—, —C1-3 alkyl- or —CH2—C(O)—;
• L is a bond, —C1-7 alkyl- or —C1-7 alkenyl-;
• R1 is hydrogen, C1-7 alkyl, C1-7 alkoxy, halogen, hydroxy, nitro, halogen C1-7 alkyl, hydroxy C1-7 alkyl, —O-halogen C1-7 alkyl or —X—NR6R7;
• R2 is hydrogen, hydroxy, C1-7 alkyl or halogen;
• R3 is hydrogen, C1-7 alkyl or amino;
• R4 is hydrogen, C1-7 alkyl, C1-7 alkoxy, halogen, hydroxy, hydroxy C1-7 alkyl, halogen C1-7 alkyl or —C(O)—O—C1-7 alkyl;
• R5 is hydrogen, halogen, C1-7 alkoxy or C1-7 alkyl;
• X is a bond or C1-7 alkyl;
• and
• R6 and R7 are, independently, hydrogen or C1-7 alkyl;
• ii) when B is
• then
• A is a 3-10 membered carbocyclyl or a 4-12 membered heterocyclyl containing 1-4 heteroatoms selected from O, N, and S;
• C is:
• G1 is CH2, NH or O;
• G2 and G3 are, independently, CH or N;
• Z is —C(O)—, —SO2—, —C1-3 alkyl- or —CH2—C(O)—;
• L is a bond, —C1-7 alkyl- or —C1-7 alkenyl-;
• R1 is hydrogen, C1-7 alkyl, C1-7 alkoxy, halogen, hydroxy, nitro, halogen C1-7 alkyl, hydroxy C1-7 alkyl, —O-halogen C1-7 alkyl or —X—NR6R7;
• R2 is hydrogen, hydroxy, C1-7 alkyl or halogen;
• R3 is hydrogen, C1-7 alkyl or amino;
• R4 is hydrogen, C1-7 alkyl, C1-7 alkoxy, halogen, hydroxy, hydroxy C1-7 alkyl, halogen C1-7 alkyl or —C(O)—O—C1-7 alkyl;
• R5 is hydrogen, halogen, C1-7 alkoxy or C1-7 alkyl;
• X is a bond or C1-7 alkyl;
• and
• R6 and R7 are, independently, hydrogen or C1-7 alkyl;
• and
• iii) when B is
• then
• A is
• provided that when C is ring (3′), then A is not ring (2″) or ring (7″);
• C is
• G1 is CH2, NH or O;
• G2 and G3 are, independently, CH or N;
• Z is —C(O)—, —SO2—, —C1-3 alkyl- or —CH2—C(O)—;
• L is a bond, —C1-7 alkyl- or —C1-7 alkenyl-;
• R1 is hydrogen, C1-7 alkyl, C1-7 alkoxy, halogen, hydroxy, halogen C1-7 alkyl, hydroxy C1-7 alkyl, —O-halogen C1-7 alkyl, or —X—NR6R7,
• R2 is hydrogen, hydroxy, C1-7 alkyl or halogen;
• R3 is hydrogen, C1-7 alkyl, or amino;
• R4 is hydrogen, C1-7 alkyl, C1-7 alkoxy, halogen, hydroxy C1-7 alkyl, halogen C1-7 alkyl or —C(O)—O—C1-7 alkyl;
• R5 is hydrogen, halogen, C1-7 alkoxy, or C1-7 alkyl;
• X is a bond or C1-7 alkyl;
• and
• R6 and R7 are, independently, hydrogen, or C1-7 alkyl;
• with the proviso that the compound of formula (I) is not:
• (3,4-Dihydro-3-methoxy-1(2H)-quinolinyl)(6-phenyl-4-pyridazinyl)methanone;
• (6-Fluoro-3,4-dihydro-4-methyl-1(2H)-quinoxalinyl)(5-phenyl-3-pyridinyl)methanone;
• (3,4-Dihydro-1(2H)-quinolinyl)(5-phenyl-3-pyridinyl)methanone;
• (5-(2,3-Dihydro-5-benzofuranyl)-3-pyridinyl)(3,4-dihydro-1(2H)-quinolinyl)methanone;
• (5-(2,3-Dihydro-5-benzofuranyl)-3-pyridinyl)(7-fluoro-2,3-dihydro-4H-1,4-benzoxazin-4-yl)methanone;
• (6,8-Difluoro-3,4-dihydro-1(2H)-quinolinyl)(5-(4-(dimethylamino)phenyl)-3-pyridinyl)methanone;
• (3,4-Dihydro-1(2H)-quinolinyl)(5-(1-pyrrolidinyl)-3-pyridinyl)methanone;
• (5-(2,3-Dihydro-5-benzofuranyl)-3-pyridinyl)(octahydro-4H-1,4-benzoxazin-4-yl)methanone;
• (5-(4-Methoxyphenyl)-3-pyridinyl)(octahydro-4H-1,4-benzoxazin-4-yl)methanone or
• (2,3-Dihydro-1H-indol-1-yl)(5-phenyl-3-pyridinyl)methanone.